Drug intelligence / Profile preview

bryostatin-22

Development stage
Preclinical
Lead developer
Synaptogenix
Modality
Small Molecules
Administration
Intravenous
01

Overview

Bryostatin-22 is a naturally occurring macrolide lactone belonging to the bryostatin family, originally isolated from the marine bryozoan *Bugula neritina*. Like its more widely studied relative, bryostatin-1, bryostatin-22 acts as a potent modulator of protein kinase C (PKC) by binding to the C1 regulatory domain of the enzyme. This binding typically induces a biphasic response characterized by an initial, transient activation of PKC followed by its rapid proteolytic degradation and subsequent downregulation. While bryostatin-1 has been extensively investigated in clinical trials for oncology, Alzheimer's disease, and HIV latency reversal, bryostatin-22 remains primarily a subject of preclinical research. It is frequently utilized in structure-activity relationship (SAR) studies to determine how specific substitutions on the bryostatin scaffold, such as the acetate group at the C20 position, influence binding affinity and biological potency across different PKC isoforms.

Other names
Bryostatin 22Bryostatin22Bryostatin-22
02

Targets

PKC (Protein kinase C family)

Beyond the preview

Go deeper on bryostatin-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bryostatin-22.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call